Castle Biosciences Inc reports results for the quarter ended in June - Earnings Summary

Castle Biosciences

02/08/2023 22:43

* Castle Biosciences Inc  CSTL.OQ  reported a quarterly
adjusted
loss of 70 cents​​ per share for the quarter ended in June. The
mean expectation of eight analysts for the quarter was for a
loss of 91 cents per share.
    * Revenue rose 43.9% to $50.14 million from a year ago;
analysts
expected $44.19 million. 
    * Castle Biosciences Inc's reported EPS for the quarter was
a loss
of 70 cents​.
    * The mean earnings estimate of analysts had fallen by
about 7.2%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate 
    * Castle Biosciences Inc shares had risen by 21.9% this
quarter and lost 29.0% so far this year.
    * The company reported a quarterly loss of $18.78 million.
    * Wall Street's median 12-month price target for Castle
Biosciences Inc is $34.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 8 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 2 at 09:42 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.91          -0.70          Beat
 Mar. 31 2023      -0.89          -1.10          Missed
 Dec. 31 2022      -0.84          -0.78          Beat
 Sep. 30 2022      -0.88          -0.77          Beat